Status:
COMPLETED
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult...
Eligibility Criteria
Inclusion
- Patient will need to read, understand and sign an informed consent prior to any study specific procedures
- Patient will have certain schizophrenia symptoms deemed by the investigator as appropriate for the study entry
Exclusion
- Patients will be excluded based on recent history of significant illness or current disease as assessed by the investigator during screening process (based on physical examination, laboratory studies and electrocardiogram studies)
- Patients will be excluded if urine drug screen test show positive results
- Smoking of more than 2 packs of cigarettes a day
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT00921804
Start Date
June 1 2009
End Date
May 1 2010
Last Update
June 30 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Garden Grove, California, United States
2
Research Site
Glendale, California, United States
3
Research Site
Rockville, Maryland, United States